More cuts to come as Teva targets US$3bn
Executive Summary
Teva is on track to achieve its targeted US$3 billion spending reduction by the end of 2019, according to president and chief executive officer Kåre Schultz. Ridding the firm of a number of its facilities and cutting staff by more than 9,000 has already produced efficiencies of US$1.8 billion in 2018.